Stefano Caruso

机构：Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Institut Mondor de Recherche Biomédicale · ORCID：0000-0002-6319-3642

发表论文 165 篇 · 总被引 5188 次 · h-index 41

代表论文

• Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study (2023 · The Lancet Oncology · 被引 117)
• Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma (2023 · Nature Communications · 被引 80)
• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 52)
• Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence (2023 · Surgery · 被引 20)
• RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis (2023 · Journal of Hepatology · 被引 12)
• DLK1/DIO3 locus upregulation by a β-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis (2024 · Molecular Therapy · 被引 11)